Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Lorelei Mucci, Sc.D.

Co-Author

This page shows the publications co-authored by Lorelei Mucci and Adam Kibel.
Connection Strength

2.761
  1. 5-alpha reductase inhibitors and prostate cancer mortality among men with regular access to screening and health care. Cancer Epidemiol Biomarkers Prev. 2022 Mar 04.
    View in: PubMed
    Score: 0.248
  2. Metabolic syndrome and its pharmacologic treatment are associated with the time to castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2022 Jan 24.
    View in: PubMed
    Score: 0.246
  3. DNA Repair Pathways and Their Association With Lethal Prostate Cancer in African American and European American Men. JNCI Cancer Spectr. 2022 02; 6(1).
    View in: PubMed
    Score: 0.244
  4. Evaluation of a Multiethnic Polygenic Risk Score Model for Prostate Cancer. J Natl Cancer Inst. 2021 Apr 01.
    View in: PubMed
    Score: 0.232
  5. Insulinemic and Inflammatory Dietary Patterns and Risk of Prostate Cancer. Eur Urol. 2021 03; 79(3):405-412.
    View in: PubMed
    Score: 0.228
  6. Meat, Fish, Poultry, and Egg Intake at Diagnosis and Risk of Prostate Cancer Progression. Cancer Prev Res (Phila). 2016 Dec; 9(12):933-941.
    View in: PubMed
    Score: 0.170
  7. Baseline Prostate-Specific Antigen Levels in Midlife Predict Lethal Prostate Cancer. J Clin Oncol. 2016 08 10; 34(23):2705-11.
    View in: PubMed
    Score: 0.166
  8. Calcium intake, polymorphisms of the calcium-sensing receptor, and recurrent/aggressive prostate cancer. Cancer Causes Control. 2015 Dec; 26(12):1751-9.
    View in: PubMed
    Score: 0.158
  9. Prostate cancer risk stratification improvement across multiple ancestries with new polygenic hazard score. Prostate Cancer Prostatic Dis. 2022 Feb 12.
    View in: PubMed
    Score: 0.062
  10. Publisher Correction: Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. Nat Genet. 2021 Mar; 53(3):413.
    View in: PubMed
    Score: 0.058
  11. Polygenic hazard score is associated with prostate cancer in multi-ethnic populations. Nat Commun. 2021 02 23; 12(1):1236.
    View in: PubMed
    Score: 0.058
  12. Additional SNPs improve risk stratification of a polygenic hazard score for prostate cancer. Prostate Cancer Prostatic Dis. 2021 06; 24(2):532-541.
    View in: PubMed
    Score: 0.057
  13. Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. Nat Genet. 2021 01; 53(1):65-75.
    View in: PubMed
    Score: 0.057
  14. Assessment of Time-to-Treatment Initiation and Survival in a Cohort of Patients With Common Cancers. JAMA Netw Open. 2020 12 01; 3(12):e2030072.
    View in: PubMed
    Score: 0.057
  15. The CHEK2 Variant C.349A>G Is Associated with Prostate Cancer Risk and Carriers Share a Common Ancestor. Cancers (Basel). 2020 Nov 04; 12(11).
    View in: PubMed
    Score: 0.056
  16. Risk of dementia following androgen deprivation therapy for treatment of prostate cancer. Prostate Cancer Prostatic Dis. 2020 09; 23(3):410-418.
    View in: PubMed
    Score: 0.053
  17. Publisher Correction: Shared heritability and functional enrichment across six solid cancers. Nat Commun. 2019 Sep 23; 10(1):4386.
    View in: PubMed
    Score: 0.052
  18. Author Correction: Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. Nat Genet. 2019 02; 51(2):363.
    View in: PubMed
    Score: 0.050
  19. Shared heritability and functional enrichment across six solid cancers. Nat Commun. 2019 01 25; 10(1):431.
    View in: PubMed
    Score: 0.050
  20. Author Correction: Germline variation at 8q24 and prostate cancer risk in men of European ancestry. Nat Commun. 2019 01 17; 10(1):382.
    View in: PubMed
    Score: 0.050
  21. Germline variation at 8q24 and prostate cancer risk in men of European ancestry. Nat Commun. 2018 11 05; 9(1):4616.
    View in: PubMed
    Score: 0.049
  22. Circulating Metabolic Biomarkers of Screen-Detected Prostate Cancer in the ProtecT Study. Cancer Epidemiol Biomarkers Prev. 2019 01; 28(1):208-216.
    View in: PubMed
    Score: 0.049
  23. Baseline Prostate-specific Antigen Level in Midlife and Aggressive Prostate Cancer in Black Men. Eur Urol. 2019 03; 75(3):399-407.
    View in: PubMed
    Score: 0.049
  24. Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. Nat Genet. 2018 07; 50(7):928-936.
    View in: PubMed
    Score: 0.048
  25. Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants. Nat Commun. 2018 06 11; 9(1):2256.
    View in: PubMed
    Score: 0.048
  26. Liver Disease in Men Undergoing Androgen Deprivation Therapy for Prostate Cancer. J Urol. 2018 09; 200(3):573-581.
    View in: PubMed
    Score: 0.047
  27. Cognitive Impairment in Men with Prostate Cancer Treated with Androgen Deprivation Therapy: A Systematic Review and Meta-Analysis. J Urol. 2018 06; 199(6):1417-1425.
    View in: PubMed
    Score: 0.047
  28. A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer. Nat Genet. 2014 Oct; 46(10):1103-9.
    View in: PubMed
    Score: 0.037
  29. Prostate cancer (PCa) risk variants and risk of fatal PCa in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. Eur Urol. 2014 Jun; 65(6):1069-75.
    View in: PubMed
    Score: 0.035
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.